Lenalidomide and Dexamethasone Asymptomatic multiple Myeloma with high Risk of Disease Progression

被引：0
|
作者：
Ahlborn, M. [1 ]
机构：
[1] Stadt Klinikum Braunschweig, Med Klin 3, D-38114 Braunschweig, Germany
来源：
ONKOLOGE | 2013年 / 19卷 / 12期
关键词：
D O I：
10.1007/s00761-013-2591-0
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1076 / 1077
页数：2
相关论文
共 50 条
  • [31] Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma
    Dimopoulos, Meletios
    Spencer, Andrew
    Attal, Michael
    Prince, H. Miles
    Harousseau, Jean-Luc
    Dmoszynska, Anna
    San Miguel, Jesus
    Hellmann, Andrzej
    Facon, Thierry
    Foa, Robin
    Corso, Alessandro
    Masliak, Zvenyslava
    Olesnyckyj, Marta
    Yu, Zhinuan
    Patin, John
    Zeldis, Jerome B.
    Knight, Robert D.
    NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (21): : 2123 - 2132
  • [32] Opposing Effects of Dexamethasone on Lenalidomide Activity in Multiple Myeloma
    Schafer, P. H.
    Gandhi, A. K.
    Zhang, L. H.
    Kang, J.
    Capone, L.
    Parton, S.
    Wu, L.
    Bartlett, B.
    CLINICAL LYMPHOMA & MYELOMA, 2009, 9 : S135 - S135
  • [33] Clarithromycin overcomes resistance to lenalidomide and dexamethasone in multiple myeloma
    Ghosh, Nilanjan
    Tucker, Noah
    Zahurak, Marianna
    Wozney, Jocelyn
    Borrello, Ivan
    Huff, Carol Ann
    AMERICAN JOURNAL OF HEMATOLOGY, 2014, 89 (08) : E116 - E120
  • [34] Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma
    Dabkara, Deepak
    Bajpai, Jyoti
    INDIAN JOURNAL OF MEDICAL AND PAEDIATRIC ONCOLOGY, 2008, 29 (03) : 10 - 13
  • [35] Lenalidomide, Bortezomib, and Dexamethasone Is Active in High-Risk Relapsed/Refractory Myeloma
    Richardson, P. G.
    Hideshima, T.
    Jagannath, S.
    Jakubowiak, A.
    Lonial, S.
    Raje, N.
    Alsina, M.
    Ghobrial, I. M.
    Schlossman, R.
    Mazumder, A.
    Munshi, N. C.
    Vesole, D.
    Colson
    McKenney
    Lunde
    Kennedy
    Kosakowski
    Mitsiades, C.
    Knight
    Esseltine
    Anderson, K. C.
    CLINICAL LYMPHOMA & MYELOMA, 2009, 9 : S38 - S38
  • [36] Carfilzomib-Lenalidomide-Dexamethasone in the Management of Lenalidomide-Refractory Multiple Myeloma
    Cerchione, Claudio
    Catalano, Lucio
    Nappi, Davide
    Pareto, Anna Emanuele
    Musuraca, Gerardo
    Lucchesi, Alessandro
    Pane, Fabrizio
    Martinelli, Giovanni
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S310 - S310
  • [37] Carfilzomib-Lenalidomide-Dexamethasone in the Management of Lenalidomide-Refractory Multiple Myeloma
    Cerchione, Claudio
    Martinelli, Giovanni
    Catalano, Lucio
    AMERICAN JOURNAL OF HEMATOLOGY, 2020, 95 : S5 - S6
  • [38] Carfilzomib-Lenalidomide-Dexamethasone in the Management of Lenalidomide-Refractory Multiple Myeloma
    Cerchione, Claudio
    Martinelli, Giovanni
    Nappi, Davide
    Pareto, Anna Emanuele
    Di Perna, Maria
    Ronconi, Sonia
    Pane, Fabrizio
    Catalano, Lucio
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E358 - E359
  • [39] Increased risk of arterial thromboembolic events with combination lenalidomide/dexamethasone therapy for multiple myeloma
    Maharaj, Satish
    Chang, Simone
    Seegobin, Karan
    Serrano-Santiago, Ivan
    Zuberi, Lara
    EXPERT REVIEW OF ANTICANCER THERAPY, 2017, 17 (07) : 585 - 591
  • [40] Carfilzomib-Lenalidomide-Dexamethasone in the Management of Lenalidomide-Refractory Multiple Myeloma
    Cerchione, Claudio
    Ferrara, Katia
    Peluso, Ilaria
    Di Perna, Maria
    Nappi, Davide
    Pareto, Anna Emanuele
    Pane, Fabrizio
    Catalano, Lucio
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 : S255 - S255
12345